| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 148 | 2023 | 432 | 35.470 |
Why?
|
| Rhinitis | 137 | 2023 | 383 | 33.790 |
Why?
|
| Endoscopy | 89 | 2023 | 464 | 14.820 |
Why?
|
| Nasal Polyps | 58 | 2023 | 184 | 13.750 |
Why?
|
| Olfaction Disorders | 37 | 2022 | 100 | 12.640 |
Why?
|
| Chronic Disease | 140 | 2023 | 1330 | 9.290 |
Why?
|
| Paranasal Sinuses | 41 | 2021 | 165 | 7.140 |
Why?
|
| Quality of Life | 64 | 2023 | 1515 | 6.510 |
Why?
|
| Smell | 36 | 2022 | 131 | 5.720 |
Why?
|
| Surveys and Questionnaires | 32 | 2021 | 2800 | 3.710 |
Why?
|
| Nasal Cavity | 12 | 2021 | 62 | 3.480 |
Why?
|
| Humans | 200 | 2023 | 68618 | 2.810 |
Why?
|
| Middle Aged | 104 | 2022 | 21147 | 2.610 |
Why?
|
| Prospective Studies | 52 | 2023 | 3705 | 2.610 |
Why?
|
| Adult | 94 | 2022 | 21403 | 2.460 |
Why?
|
| Nasal Mucosa | 6 | 2021 | 68 | 2.380 |
Why?
|
| Aged | 74 | 2021 | 14862 | 2.150 |
Why?
|
| Rhinitis, Allergic | 5 | 2021 | 22 | 2.150 |
Why?
|
| Nasal Surgical Procedures | 5 | 2019 | 21 | 2.080 |
Why?
|
| Male | 109 | 2023 | 37321 | 2.050 |
Why?
|
| Female | 110 | 2023 | 38074 | 2.030 |
Why?
|
| Treatment Outcome | 55 | 2023 | 7029 | 1.960 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 7 | 2016 | 62 | 1.950 |
Why?
|
| Depression | 7 | 2018 | 943 | 1.820 |
Why?
|
| Tomography, X-Ray Computed | 21 | 2019 | 2324 | 1.770 |
Why?
|
| Patient Reported Outcome Measures | 9 | 2022 | 114 | 1.680 |
Why?
|
| Sleep Wake Disorders | 4 | 2018 | 94 | 1.640 |
Why?
|
| Anti-Bacterial Agents | 15 | 2019 | 1026 | 1.620 |
Why?
|
| Young Adult | 36 | 2021 | 5717 | 1.570 |
Why?
|
| Cytokines | 6 | 2021 | 866 | 1.570 |
Why?
|
| Cognitive Dysfunction | 3 | 2019 | 176 | 1.500 |
Why?
|
| Reoperation | 11 | 2020 | 467 | 1.440 |
Why?
|
| Efficiency | 4 | 2019 | 49 | 1.280 |
Why?
|
| Mycoses | 3 | 2020 | 60 | 1.250 |
Why?
|
| Fatigue | 3 | 2019 | 132 | 1.240 |
Why?
|
| Mucus | 6 | 2021 | 33 | 1.210 |
Why?
|
| Sleep | 4 | 2020 | 263 | 1.200 |
Why?
|
| Biological Products | 3 | 2023 | 78 | 1.160 |
Why?
|
| Severity of Illness Index | 19 | 2019 | 1851 | 1.120 |
Why?
|
| Asthma | 5 | 2019 | 345 | 1.120 |
Why?
|
| Nasal Obstruction | 5 | 2020 | 34 | 1.060 |
Why?
|
| Olfactory Mucosa | 3 | 2019 | 11 | 1.030 |
Why?
|
| Steroids | 6 | 2020 | 84 | 1.020 |
Why?
|
| Health Status Indicators | 3 | 2018 | 117 | 1.010 |
Why?
|
| Cohort Studies | 22 | 2020 | 2358 | 0.990 |
Why?
|
| Paranasal Sinus Diseases | 3 | 2015 | 30 | 0.960 |
Why?
|
| Adrenal Cortex Hormones | 9 | 2022 | 186 | 0.950 |
Why?
|
| Epistaxis | 2 | 2021 | 6 | 0.940 |
Why?
|
| Desensitization, Immunologic | 2 | 2014 | 25 | 0.940 |
Why?
|
| Adolescent | 23 | 2020 | 8912 | 0.880 |
Why?
|
| Pituitary Neoplasms | 4 | 2016 | 52 | 0.850 |
Why?
|
| Ethmoid Sinus | 6 | 2016 | 15 | 0.850 |
Why?
|
| Case-Control Studies | 11 | 2021 | 1553 | 0.840 |
Why?
|
| Cost of Illness | 4 | 2023 | 206 | 0.820 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 2 | 2012 | 41 | 0.820 |
Why?
|
| United States | 20 | 2021 | 7367 | 0.820 |
Why?
|
| Follow-Up Studies | 19 | 2020 | 3259 | 0.820 |
Why?
|
| Comorbidity | 10 | 2021 | 1426 | 0.800 |
Why?
|
| Therapeutic Irrigation | 3 | 2019 | 63 | 0.800 |
Why?
|
| Cautery | 1 | 2021 | 5 | 0.780 |
Why?
|
| Silver Nitrate | 1 | 2021 | 6 | 0.780 |
Why?
|
| Maxillary Sinus | 2 | 2019 | 12 | 0.780 |
Why?
|
| Checklist | 2 | 2012 | 76 | 0.770 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 4848 | 0.770 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 45 | 0.740 |
Why?
|
| Maxillary Sinusitis | 2 | 2019 | 7 | 0.710 |
Why?
|
| Absenteeism | 4 | 2018 | 27 | 0.700 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 24 | 0.700 |
Why?
|
| Postoperative Complications | 9 | 2017 | 1615 | 0.690 |
Why?
|
| Heart Diseases | 1 | 2022 | 276 | 0.690 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2019 | 14 | 0.680 |
Why?
|
| Amebiasis | 1 | 2019 | 6 | 0.660 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.640 |
Why?
|
| Water Supply | 1 | 2019 | 54 | 0.640 |
Why?
|
| Evidence-Based Medicine | 5 | 2014 | 438 | 0.630 |
Why?
|
| Antifungal Agents | 3 | 2015 | 108 | 0.630 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2018 | 8 | 0.630 |
Why?
|
| Cryotherapy | 1 | 2018 | 36 | 0.630 |
Why?
|
| Dysgeusia | 1 | 2018 | 4 | 0.620 |
Why?
|
| Cluster Analysis | 4 | 2022 | 219 | 0.620 |
Why?
|
| Prevalence | 8 | 2020 | 1619 | 0.590 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.580 |
Why?
|
| Catheterization | 2 | 2017 | 209 | 0.560 |
Why?
|
| Adenoma | 2 | 2015 | 132 | 0.550 |
Why?
|
| Child | 13 | 2019 | 6405 | 0.540 |
Why?
|
| Patient Selection | 6 | 2018 | 592 | 0.540 |
Why?
|
| Eosinophilia | 3 | 2014 | 47 | 0.540 |
Why?
|
| Respiratory System Agents | 1 | 2016 | 4 | 0.540 |
Why?
|
| Otologic Surgical Procedures | 1 | 2016 | 23 | 0.540 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.530 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 35 | 0.530 |
Why?
|
| Symptom Assessment | 1 | 2015 | 33 | 0.510 |
Why?
|
| Quality of Health Care | 2 | 2018 | 322 | 0.510 |
Why?
|
| Headache | 2 | 2022 | 68 | 0.500 |
Why?
|
| Cost Savings | 1 | 2015 | 110 | 0.490 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 109 | 0.490 |
Why?
|
| Craniotomy | 2 | 2012 | 33 | 0.480 |
Why?
|
| Osteotomy | 2 | 2015 | 46 | 0.480 |
Why?
|
| Hypophysectomy | 1 | 2014 | 5 | 0.480 |
Why?
|
| Frontal Sinusitis | 2 | 2016 | 5 | 0.470 |
Why?
|
| Macrolides | 2 | 2015 | 48 | 0.470 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 2279 | 0.470 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 3 | 0.470 |
Why?
|
| Disease Management | 1 | 2016 | 248 | 0.470 |
Why?
|
| Microsurgery | 1 | 2014 | 46 | 0.470 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 191 | 0.460 |
Why?
|
| Natural Orifice Endoscopic Surgery | 4 | 2020 | 24 | 0.460 |
Why?
|
| Frontal Sinus | 3 | 2016 | 14 | 0.460 |
Why?
|
| Cilia | 1 | 2014 | 94 | 0.450 |
Why?
|
| Bandages | 1 | 2013 | 33 | 0.450 |
Why?
|
| Ethmoid Sinusitis | 2 | 2011 | 2 | 0.440 |
Why?
|
| Facial Pain | 2 | 2014 | 8 | 0.440 |
Why?
|
| Prognosis | 8 | 2018 | 2093 | 0.430 |
Why?
|
| Intracranial Hypotension | 1 | 2012 | 4 | 0.430 |
Why?
|
| Dilatation | 3 | 2018 | 58 | 0.430 |
Why?
|
| Age Factors | 7 | 2020 | 1864 | 0.430 |
Why?
|
| Exhalation | 3 | 2022 | 7 | 0.420 |
Why?
|
| Fluticasone | 3 | 2022 | 12 | 0.420 |
Why?
|
| Intracranial Pressure | 1 | 2012 | 58 | 0.420 |
Why?
|
| Rhinoplasty | 2 | 2012 | 27 | 0.410 |
Why?
|
| Alberta | 3 | 2017 | 15 | 0.410 |
Why?
|
| Cognition Disorders | 1 | 2015 | 342 | 0.410 |
Why?
|
| Retrospective Studies | 15 | 2020 | 7277 | 0.410 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2012 | 10 | 0.410 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.400 |
Why?
|
| Odorants | 4 | 2022 | 52 | 0.400 |
Why?
|
| Face | 1 | 2012 | 46 | 0.400 |
Why?
|
| Nose Neoplasms | 1 | 2012 | 25 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 504 | 0.390 |
Why?
|
| Cystic Fibrosis | 1 | 2015 | 283 | 0.390 |
Why?
|
| Cerebrospinal Fluid Leak | 4 | 2016 | 32 | 0.380 |
Why?
|
| Disease Progression | 6 | 2016 | 1038 | 0.380 |
Why?
|
| Pneumocephalus | 2 | 2016 | 12 | 0.370 |
Why?
|
| Graves Disease | 1 | 2010 | 8 | 0.370 |
Why?
|
| Risk Factors | 10 | 2020 | 5731 | 0.370 |
Why?
|
| Sphenoid Sinusitis | 1 | 2010 | 4 | 0.370 |
Why?
|
| Sphenoid Bone | 1 | 2010 | 4 | 0.370 |
Why?
|
| Turbinates | 1 | 2010 | 12 | 0.360 |
Why?
|
| Physician-Patient Relations | 3 | 2019 | 261 | 0.350 |
Why?
|
| Taste | 3 | 2018 | 49 | 0.350 |
Why?
|
| Eustachian Tube | 2 | 2022 | 31 | 0.350 |
Why?
|
| Ear Diseases | 2 | 2022 | 37 | 0.350 |
Why?
|
| Quality Improvement | 4 | 2018 | 413 | 0.340 |
Why?
|
| Malacoplakia | 1 | 2009 | 3 | 0.340 |
Why?
|
| Presenteeism | 3 | 2019 | 7 | 0.340 |
Why?
|
| Mucocele | 1 | 2009 | 20 | 0.340 |
Why?
|
| Hypersensitivity | 2 | 2022 | 52 | 0.330 |
Why?
|
| Meningeal Neoplasms | 1 | 2009 | 42 | 0.330 |
Why?
|
| Time Factors | 6 | 2016 | 4655 | 0.320 |
Why?
|
| Ethmoid Bone | 2 | 2019 | 18 | 0.320 |
Why?
|
| Meningioma | 1 | 2009 | 54 | 0.320 |
Why?
|
| Pilot Projects | 3 | 2021 | 1342 | 0.320 |
Why?
|
| Facial Nerve | 1 | 2008 | 25 | 0.320 |
Why?
|
| Consensus | 4 | 2022 | 211 | 0.320 |
Why?
|
| Surgical Flaps | 1 | 2009 | 120 | 0.310 |
Why?
|
| Canada | 4 | 2016 | 267 | 0.310 |
Why?
|
| Olfactory Bulb | 2 | 2019 | 14 | 0.310 |
Why?
|
| Fibromyalgia | 1 | 2008 | 29 | 0.310 |
Why?
|
| Health Status | 3 | 2020 | 429 | 0.300 |
Why?
|
| Phenotype | 3 | 2022 | 947 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2077 | 0.280 |
Why?
|
| Otolaryngology | 2 | 2018 | 38 | 0.280 |
Why?
|
| Models, Economic | 3 | 2014 | 69 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 931 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 504 | 0.260 |
Why?
|
| Cholecalciferol | 3 | 2016 | 143 | 0.250 |
Why?
|
| Nasal Septum | 2 | 2017 | 16 | 0.250 |
Why?
|
| Pain Measurement | 3 | 2013 | 328 | 0.250 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2017 | 127 | 0.250 |
Why?
|
| Leukotriene Antagonists | 2 | 2015 | 13 | 0.250 |
Why?
|
| Sphenoid Sinus | 2 | 2015 | 10 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 2223 | 0.240 |
Why?
|
| Logistic Models | 4 | 2016 | 1420 | 0.230 |
Why?
|
| Epithelial Cells | 2 | 2017 | 431 | 0.230 |
Why?
|
| Preoperative Care | 2 | 2018 | 275 | 0.220 |
Why?
|
| Inflammation | 3 | 2019 | 1030 | 0.220 |
Why?
|
| Sex Factors | 2 | 2018 | 1266 | 0.220 |
Why?
|
| Recurrence | 3 | 2021 | 948 | 0.220 |
Why?
|
| Nasal Sprays | 2 | 2020 | 11 | 0.210 |
Why?
|
| Physical Examination | 2 | 2021 | 152 | 0.210 |
Why?
|
| Benchmarking | 1 | 2023 | 91 | 0.210 |
Why?
|
| Biomarkers | 3 | 2021 | 1593 | 0.210 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2019 | 29 | 0.210 |
Why?
|
| Fibroblasts | 3 | 2016 | 902 | 0.210 |
Why?
|
| Social Support | 2 | 2016 | 423 | 0.200 |
Why?
|
| Vitamin D Deficiency | 2 | 2016 | 292 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2016 | 3187 | 0.200 |
Why?
|
| Algorithms | 3 | 2021 | 1196 | 0.200 |
Why?
|
| Research Design | 2 | 2015 | 729 | 0.190 |
Why?
|
| Postoperative Period | 3 | 2018 | 238 | 0.190 |
Why?
|
| Societies, Medical | 3 | 2018 | 403 | 0.190 |
Why?
|
| Postoperative Care | 2 | 2011 | 163 | 0.190 |
Why?
|
| Decision Making | 2 | 2014 | 410 | 0.180 |
Why?
|
| Loneliness | 1 | 2020 | 20 | 0.180 |
Why?
|
| Population Groups | 1 | 2020 | 16 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1140 | 0.180 |
Why?
|
| Decision Trees | 3 | 2014 | 74 | 0.180 |
Why?
|
| Acoustics | 1 | 2020 | 20 | 0.180 |
Why?
|
| Olfactory Perception | 1 | 2020 | 20 | 0.180 |
Why?
|
| Proteome | 1 | 2020 | 87 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 2 | 2018 | 201 | 0.180 |
Why?
|
| Vibration | 1 | 2020 | 32 | 0.170 |
Why?
|
| Costs and Cost Analysis | 3 | 2015 | 193 | 0.170 |
Why?
|
| Biometry | 1 | 2020 | 72 | 0.170 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.170 |
Why?
|
| Thinking | 1 | 2019 | 30 | 0.170 |
Why?
|
| Pain Management | 1 | 2021 | 186 | 0.170 |
Why?
|
| Skull Base | 2 | 2018 | 72 | 0.170 |
Why?
|
| Pressure | 1 | 2020 | 252 | 0.170 |
Why?
|
| Administration, Intranasal | 2 | 2022 | 88 | 0.170 |
Why?
|
| Historically Controlled Study | 1 | 2019 | 7 | 0.170 |
Why?
|
| Drug Utilization | 2 | 2017 | 119 | 0.170 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 214 | 0.160 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2019 | 48 | 0.160 |
Why?
|
| Health Communication | 1 | 2019 | 19 | 0.160 |
Why?
|
| Social Class | 1 | 2019 | 127 | 0.160 |
Why?
|
| Denervation | 1 | 2018 | 23 | 0.160 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 42 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2017 | 222 | 0.160 |
Why?
|
| Workplace | 1 | 2019 | 75 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2019 | 111 | 0.160 |
Why?
|
| Psychometrics | 1 | 2021 | 514 | 0.160 |
Why?
|
| Antigens, Fungal | 2 | 2015 | 19 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 64 | 0.150 |
Why?
|
| Diet | 1 | 2021 | 514 | 0.150 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 133 | 0.150 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.150 |
Why?
|
| Perforin | 1 | 2017 | 12 | 0.150 |
Why?
|
| Granzymes | 1 | 2017 | 19 | 0.150 |
Why?
|
| Sodium Chloride | 2 | 2015 | 136 | 0.150 |
Why?
|
| Nose Diseases | 1 | 2017 | 8 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 117 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2014 | 106 | 0.150 |
Why?
|
| Markov Chains | 2 | 2014 | 133 | 0.140 |
Why?
|
| Feeding and Eating Disorders | 1 | 2018 | 106 | 0.140 |
Why?
|
| Animals | 4 | 2016 | 20881 | 0.140 |
Why?
|
| Smoke | 1 | 2017 | 46 | 0.140 |
Why?
|
| Social Skills | 1 | 2016 | 14 | 0.140 |
Why?
|
| Economics | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sick Leave | 1 | 2016 | 6 | 0.140 |
Why?
|
| Craniopharyngioma | 1 | 2016 | 7 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 517 | 0.140 |
Why?
|
| Incidence | 3 | 2016 | 1603 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.140 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 104 | 0.140 |
Why?
|
| Personality | 1 | 2016 | 66 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 177 | 0.140 |
Why?
|
| Laryngoscopy | 1 | 2016 | 61 | 0.130 |
Why?
|
| North America | 1 | 2016 | 112 | 0.130 |
Why?
|
| Trust | 1 | 2016 | 75 | 0.130 |
Why?
|
| Tobacco | 1 | 2017 | 161 | 0.130 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 36 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 658 | 0.130 |
Why?
|
| Risk | 4 | 2020 | 563 | 0.130 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 21 | 0.130 |
Why?
|
| Maintenance Chemotherapy | 1 | 2015 | 10 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 129 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2016 | 880 | 0.130 |
Why?
|
| Reference Standards | 1 | 2015 | 115 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 955 | 0.130 |
Why?
|
| Histamine Antagonists | 1 | 2015 | 22 | 0.130 |
Why?
|
| Bibliometrics | 1 | 2015 | 25 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1054 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2017 | 201 | 0.130 |
Why?
|
| Patients | 1 | 2015 | 69 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 373 | 0.130 |
Why?
|
| Alternaria | 1 | 2015 | 4 | 0.130 |
Why?
|
| Doxycycline | 1 | 2015 | 49 | 0.130 |
Why?
|
| Aspergillus fumigatus | 1 | 2015 | 27 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 61 | 0.130 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 27 | 0.120 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2014 | 14 | 0.120 |
Why?
|
| Administration, Sublingual | 1 | 2014 | 15 | 0.120 |
Why?
|
| Focus Groups | 1 | 2015 | 247 | 0.120 |
Why?
|
| Motivation | 1 | 2019 | 561 | 0.120 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2015 | 52 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 341 | 0.120 |
Why?
|
| Oregon | 1 | 2014 | 7 | 0.120 |
Why?
|
| Nose | 1 | 2014 | 36 | 0.120 |
Why?
|
| California | 1 | 2014 | 99 | 0.120 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 149 | 0.120 |
Why?
|
| Hair | 1 | 2014 | 46 | 0.120 |
Why?
|
| Vitamins | 1 | 2015 | 134 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.120 |
Why?
|
| Respiratory Mucosa | 1 | 2014 | 52 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 597 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2012 | 234 | 0.110 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2014 | 43 | 0.110 |
Why?
|
| Tissue Adhesions | 1 | 2013 | 21 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 346 | 0.110 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 16 | 0.110 |
Why?
|
| Aging | 1 | 2019 | 911 | 0.110 |
Why?
|
| Debridement | 2 | 2011 | 55 | 0.110 |
Why?
|
| Cyclopropanes | 1 | 2012 | 10 | 0.110 |
Why?
|
| Polytetrafluoroethylene | 1 | 2012 | 55 | 0.110 |
Why?
|
| Polyethylenes | 1 | 2012 | 31 | 0.110 |
Why?
|
| Immunity, Mucosal | 1 | 2012 | 19 | 0.110 |
Why?
|
| Fungi | 1 | 2012 | 27 | 0.100 |
Why?
|
| Sulfides | 1 | 2012 | 43 | 0.100 |
Why?
|
| Quinolines | 1 | 2012 | 48 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 23 | 0.100 |
Why?
|
| Minority Health | 1 | 2012 | 14 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 146 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2012 | 70 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2016 | 621 | 0.100 |
Why?
|
| Acetates | 1 | 2012 | 74 | 0.100 |
Why?
|
| South Carolina | 2 | 2020 | 2752 | 0.100 |
Why?
|
| Physicians | 1 | 2015 | 324 | 0.100 |
Why?
|
| Otitis Media | 1 | 2012 | 35 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2012 | 111 | 0.100 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 130 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 56 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 468 | 0.100 |
Why?
|
| Safety Management | 1 | 2012 | 73 | 0.100 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 159 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 150 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2012 | 156 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2012 | 99 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2012 | 239 | 0.090 |
Why?
|
| Nicotine | 1 | 2014 | 350 | 0.090 |
Why?
|
| Receptors, Thyrotropin | 1 | 2010 | 7 | 0.090 |
Why?
|
| Recovery of Function | 2 | 2014 | 506 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1465 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2012 | 247 | 0.090 |
Why?
|
| Autoantigens | 1 | 2010 | 91 | 0.090 |
Why?
|
| Foreign Bodies | 1 | 2010 | 58 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 110 | 0.090 |
Why?
|
| Reference Values | 1 | 2010 | 579 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2016 | 2007 | 0.080 |
Why?
|
| Eosinophils | 1 | 2009 | 60 | 0.080 |
Why?
|
| Cytoplasmic Granules | 1 | 2009 | 19 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 800 | 0.080 |
Why?
|
| Bone Transplantation | 1 | 2009 | 43 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 694 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 12 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 498 | 0.080 |
Why?
|
| Gene Expression | 1 | 2011 | 770 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1076 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 68 | 0.070 |
Why?
|
| Aspirin | 2 | 2022 | 295 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2018 | 50 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2550 | 0.070 |
Why?
|
| Delphi Technique | 2 | 2017 | 62 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 378 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2016 | 267 | 0.060 |
Why?
|
| Length of Stay | 2 | 2016 | 780 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 151 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 772 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2673 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 295 | 0.050 |
Why?
|
| Independent Living | 1 | 2020 | 44 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 109 | 0.040 |
Why?
|
| Receptors, Odorant | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 170 | 0.040 |
Why?
|
| Nerve Regeneration | 1 | 2019 | 42 | 0.040 |
Why?
|
| Phenylthiourea | 1 | 2018 | 2 | 0.040 |
Why?
|
| Trigeminal Nerve | 1 | 2018 | 22 | 0.040 |
Why?
|
| Drinking | 1 | 2018 | 35 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 47 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1753 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 242 | 0.040 |
Why?
|
| Hearing Tests | 1 | 2018 | 70 | 0.040 |
Why?
|
| Dissection | 1 | 2018 | 29 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 144 | 0.040 |
Why?
|
| Eating | 1 | 2018 | 119 | 0.040 |
Why?
|
| Infant | 2 | 2016 | 2891 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 136 | 0.040 |
Why?
|
| Demography | 1 | 2018 | 279 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 136 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 94 | 0.040 |
Why?
|
| Antigens | 1 | 2017 | 90 | 0.040 |
Why?
|
| Bone Density | 1 | 2018 | 159 | 0.040 |
Why?
|
| Chordoma | 1 | 2016 | 9 | 0.040 |
Why?
|
| Regional Health Planning | 1 | 2016 | 7 | 0.030 |
Why?
|
| Encephalocele | 1 | 2016 | 30 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 210 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2016 | 50 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 245 | 0.030 |
Why?
|
| Calcitriol | 1 | 2016 | 106 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 114 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2014 | 17 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 71 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 689 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2014 | 25 | 0.030 |
Why?
|
| Insurance, Surgical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Patient Participation | 1 | 2016 | 146 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2014 | 53 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2014 | 91 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 101 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 630 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 97 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 572 | 0.030 |
Why?
|
| Drug Costs | 1 | 2014 | 87 | 0.030 |
Why?
|
| Allergens | 1 | 2014 | 54 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 241 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.030 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2013 | 6 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 381 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 330 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2013 | 87 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2013 | 56 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 371 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1040 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 158 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2012 | 21 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 39 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 867 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 1752 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 6 | 0.020 |
Why?
|
| Adipokines | 1 | 2011 | 20 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1174 | 0.020 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 51 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 33 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 595 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 81 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 561 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 102 | 0.020 |
Why?
|
| Vitamin D | 1 | 2015 | 516 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 199 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 492 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2011 | 238 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1046 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 710 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 290 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 562 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 627 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 954 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 682 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 786 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2008 | 55 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 597 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 274 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 546 | 0.020 |
Why?
|